Oral treprostinil (UT-15C) sustained release tablets

DRUG3 trials

Sponsors

United Therapeutics, Brigham and Women's Hospital

Conditions

Pulmonary HypertensionRaynaud PhenomenaRaynaud's DiseaseRaynauds

Phase 3

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

CompletedNCT00325403

United TherapeuticsPulmonary Hypertension

Start: 2006-10-31End: 2011-04-30Updated: 2024-01-03

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

CompletedNCT00325442

United TherapeuticsPulmonary Hypertension

Start: 2006-10-31End: 2010-12-31Updated: 2017-08-02

Phase 4

Open Label Treprostinil Raynaud's Study

RecruitingNCT07112183

Brigham and Women's HospitalRaynaud Phenomena, Raynauds, Raynaud's Disease

Start: 2025-10-15End: 2029-03-01Target: 30Updated: 2026-03-24

Related Papers

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

2013-01-10241 citations

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

2012-12-01249 citations